CancerDrs

Pancreatic Cancer clinical trials in Indiana

22 actively recruiting pancreatic cancer trials at 12 sites across Indiana.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Indiana:
  • Northwest Cancer Center - Crown Point — Crown Point, Indiana
  • Northwest Oncology LLC — Dyer, Indiana
  • Goshen Center for Cancer Care — Goshen, Indiana
  • Northwest Cancer Center - Hobart — Hobart, Indiana
  • Saint Mary Medical Center — Hobart, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in Indiana:
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Indiana:
  • Investigative Site US021 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Indiana:
  • IU Health North Hospital — Carmel, Indiana
  • Northwest Cancer Center - Crown Point — Crown Point, Indiana
  • Northwest Oncology LLC — Dyer, Indiana
  • Saint Mary Medical Center — Hobart, Indiana
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Indiana:
  • Community Health Network — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Indiana:
  • Community Health Network — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Indiana:
  • Riley Hospital for Children — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Indiana:
  • University of Indiana — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Indiana:
  • Indiana University (IU) Health - Multi-D Oncology Clinic — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Indiana:
  • Community Health Network — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Indiana:
  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593 — Fort Wayne, Indiana
  • Community Health Network, Inc. /ID# 243011 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …

Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Indiana:
  • Indiana University (IU) School of Medicine — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Indiana:
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Recruiting Network

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Indiana:
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Indiana:
  • Parkview Research Center — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acut…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06651580
Sites in Indiana:
  • Riley Hospital for Children — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtain…

Sponsor: Ohio State University Comprehensive Cancer Center
NCT ID: NCT03492151
Sites in Indiana:
  • Parkview Hospital Randallia — Fort Wayne, Indiana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Increasing Germline Genetic Testing for Patients With Cancer

Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite o…

Sponsor: Josh Peterson
NCT ID: NCT07307664
Sites in Indiana:
  • Indiana University School of Medicine — Indianapolis, Indiana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borde…

Sponsor: Ohio State University
NCT ID: NCT06173310
Sites in Indiana:
  • Indiana University Medical Center — Indianapolis, Indiana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12